Guardant Health, Inc

General information

Guardant Health, Inc
505 Penobscot Dr.
94063 Redwood City, California
USA

Contact person: Helmy Eltoukhy, Chief Executive Officer and Chairman
Company main phone: +1 (855) 6988887
Company main fax: +1 (888) 9744258
Website: https://www.guardanthealth.com

Year founded:	2012
Source of foundation:	Independent foundation
No. of employees:	Worldwide: 1793

Corporate description / mission:
Guardant Health is a precision oncology company focused on cancer diagnostics through use of the proprietary blood tests, vast data sets and advanced analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening.

State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2018

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Molecular diagnostics
Other

Primary therapeutic areas:

Neoplasms / cancer / oncology

Business model:

Manufacturer
R&D
Service company
Supplier / Distributor

Customer segments:

Consumers (mass market)
Hospitals
Large medtech
Physicians / doctors

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Description of products:
Guardant360® CDx
Guardant Reveal™ test
LUNAR-2 test

Financing details

Fiscal year (end of) 2022

Revenues:	USD 449.54M
R&D expenses:	USD 373.81M

No. of shares:	102'664'000
Market cap. / valuation:	USD 2'664.13M

Collaborations & Clients

Partnering strategy / collaborations:
The company work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors.